Do Care Plans Include Cannabis Dosing Schedules for Dementia?

PostedMarch 12, 2026

UpdatedMarch 12, 2026

ByMy Patient Advice

Author: Julia Sutton, MSc | Reviewed by: Dr. Clarissa Morton, PharmD

As interest in medical cannabis grows, families and care professionals are asking whether cannabis dosing can be part of formal dementia care plans. In the UK, cannabis-based medicinal products (CBPMs) are legal only under specialist prescription, but there are no standard dosing schedules for dementia. Care plans can include cannabis administration only when prescribed, supervised, and documented according to national guidance.

Legal And Clinical Framework

Under the Misuse of Drugs Regulations 2001, CBPMs are Schedule 2 controlled drugs, meaning their use must follow strict NHS England and CQC procedures for prescribing, storage, and administration (NHS England, 2023).

Only specialist doctors on the General Medical Council’s register can issue prescriptions, and dementia is not an approved indication. Any inclusion of cannabis in a care plan is therefore considered off-label and must follow the same governance applied to other controlled substances.

How Care Plans Manage Medication

Care homes are required to follow NICE SC1, which sets out standards for managing medicines in care homes. Each resident must have a personalised care plan covering:

Prescribed medicines and administration times.

Dosage records on the MAR (Medication Administration Record).

Staff competency and training requirements.

Consent procedures under the Mental Capacity Act 2005.

For cannabis, care plans must also document the prescriber’s name, formulation (oil, capsule, or spray), and dose titration schedule if directed by the specialist. All doses must be recorded, witnessed, and reviewed regularly.

Because no NICE dosing guidance exists for dementia, clinicians base decisions on symptom monitoring and tolerance rather than fixed numerical schedules.

Clinical And Ethical Oversight

The CQC Controlled Drugs Annual Report 2024 emphasises that staff must maintain controlled drug registers, ensure secure storage, and dispose of unused CBPMs via authorised channels. Covert administration (giving medicine without consent) requires formal best-interest decisions and legal documentation. The Alzheimer’s Society cautions that care plans should prioritise evidence-based treatments and supportive behavioural strategies, as cannabis remains experimental for dementia.

Clinical Bottom Line

No national dosing schedules exist for cannabis in dementia care.

Care plans can include CBPMs only if prescribed and clinically justified.

All dosing must be recorded under controlled-drug and MAR procedures.

Specialists and CQC oversight are mandatory to ensure legality and safety.

Educational Context: AlleviMed

AlleviMed provides educational information about how UK clinicians determine eligibility and safe use of medical cannabis. It explains how dosing and monitoring protocols fit within legal frameworks for controlled medicines in older adults.

Takeaway

Cannabis dosing can appear in dementia care plans only when prescribed by a specialist and managed under strict controlled-drug procedures. There are no standard UK dosing guidelines for dementia, and care plans must focus on safety, consent, and regulatory compliance above all else.

Julia Sutton, MSc

Author

Julia Sutton is a clinical psychologist with a Master’s in Clinical Psychology and experience providing psychological assessment and therapy to adolescents and adults. Skilled in CBT, client-centered therapy, and evidence-based interventions, she has worked with conditions including depression, anxiety, bipolar disorder, and conversion disorder. She also has experience in child psychology, conducting psycho-educational evaluations and developing tailored treatment plans to improve learning and well-being.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the author's privacy.

Dr. Clarissa Morton, PharmD

Reviewer

Dr. Clarissa Morton is a licensed pharmacist with a Doctor of Pharmacy degree and experience across hospital, community, and industrial pharmacy. She has worked in emergency, outpatient, and inpatient pharmacy settings, providing patient counseling, dispensing medications, and ensuring regulatory compliance. Alongside her pharmacy expertise, she has worked as a Support Plan & Risk Assessment (SPRA) officer and in medical coding, applying knowledge of medical terminology, EMIS, and SystmOne software to deliver accurate, compliant healthcare documentation. Her skills span medication safety, regulatory standards, healthcare data management, and statistical reporting.

All qualifications and professional experience stated above are authentic and verified by our editorial team. However, pseudonym and image likeness are used to protect the reviewers's privacy.